News Medical18h
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
PharmaTimes3d
Libtayo available in Scotland for cervical cancer patients
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
Cure Today4d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
PharmiWeb4d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...